MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling

Here, Venkatesh et al. investigated the p53-independent roles of MDMX and the MDM2–MDMX complex. They found that MDM2 and MDMX facilitate ferroptosis in cells with or without p53, and that PPARα activity is essential for MDM2 and MDMX to promote ferroptosis, suggesting that the MDM2–MDMX complex regulates lipids through altering PPARα activity.

[1]  T. Mikkelsen,et al.  Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery , 2020, Oncotarget.

[2]  B. Stockwell,et al.  GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling , 2019, ACS central science.

[3]  Edward W. Tate,et al.  FSP1 is a glutathione-independent ferroptosis suppressor , 2019, Nature.

[4]  J. Olzmann,et al.  The CoQ oxidoreductase FSP1 acts in parallel to GPX4 to inhibit ferroptosis , 2019, Nature.

[5]  J. Olzmann,et al.  Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. , 2019, Cell chemical biology.

[6]  L. Zhuang,et al.  BAP1 suppresses tumor development by inducing ferroptosis upon SLC7A11 repression , 2018, Molecular & cellular oncology.

[7]  Mohammad A. Ghattas,et al.  Identification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening , 2018, Drug design, development and therapy.

[8]  D. Felsher,et al.  The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma , 2018, Oncogene.

[9]  J. Arnold,et al.  Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53. , 2018, Molecular cell.

[10]  S. Dixon,et al.  p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells. , 2018, Cell reports.

[11]  W. Gu,et al.  Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects , 2018, Oncotarget.

[12]  Subramaniam Pennathur,et al.  Impaired β-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[13]  B. Stockwell,et al.  Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease , 2017, Cell.

[14]  Qiaojun He,et al.  MDM2 promotes epithelial–mesenchymal transition and metastasis of ovarian cancer SKOV3 cells , 2017, British Journal of Cancer.

[15]  G. Kroemer,et al.  The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. , 2017, Cell reports.

[16]  B. Stockwell,et al.  Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure , 2017, Cellular and Molecular Life Sciences.

[17]  Xiao-Jun Ji,et al.  Reactive Oxygen Species-Mediated Cellular Stress Response and Lipid Accumulation in Oleaginous Microorganisms: The State of the Art and Future Perspectives , 2017, Front. Microbiol..

[18]  Caroline H. Johnson,et al.  PPAR&agr; regulates tumor cell proliferation and senescence via a novel target gene carnitine palmitoyltransferase 1C , 2017, Carcinogenesis.

[19]  I. Arisi,et al.  MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability , 2017, Molecular Cancer.

[20]  V. Pant,et al.  The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis , 2017, The Journal of pathology.

[21]  C. M. Eischen.  Role of Mdm2 and Mdmx in DNA repair , 2017, Journal of molecular cell biology.

[22]  U. Moll,et al.  Mdm2 as a chromatin modifier , 2016, Journal of molecular cell biology.

[23]  Allegra T. Aron,et al.  An Endoperoxide Reactivity-Based FRET Probe for Ratiometric Fluorescence Imaging of Labile Iron Pools in Living Cells , 2016, Journal of the American Chemical Society.

[24]  M. Murphy.  Ironing out how p53 regulates ferroptosis , 2016, Proceedings of the National Academy of Sciences.

[25]  W. Gu,et al.  Acetylation Is Crucial for p53-Mediated Ferroptosis and Tumor Suppression. , 2016, Cell reports.

[26]  W. Gu,et al.  Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses , 2016, Proceedings of the National Academy of Sciences.

[27]  S. Jones,et al.  The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells , 2016, Oncogenesis.

[28]  M. Barton,et al.  Outside the p53 RING: Transcription Regulation by Chromatin-Bound MDM2. , 2016, Molecular cell.

[29]  L. Linares,et al.  Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53. , 2016, Molecular cell.

[30]  J. Lunec,et al.  Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer , 2016, Oncotarget.

[31]  C. Prives,et al.  The Roles of MDM2 and MDMX in Cancer. , 2016, Annual review of pathology.

[32]  Yongmei Yin,et al.  Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo , 2016, Oncotarget.

[33]  Michelle R. Campbell,et al.  An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model , 2016, Genes & development.

[34]  Yang Zhang,et al.  MDM2 oligomers: antagonizers of the guardian of the genome , 2016, Oncogene.

[35]  Sathish Kumar Mungamuri,et al.  USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation. , 2016, Cell reports.

[36]  B. Stockwell,et al.  Global Survey of Cell Death Mechanisms Reveals Metabolic Regulation of Ferroptosis , 2016, Nature chemical biology.

[37]  B. Stockwell,et al.  Ferroptosis: Death by Lipid Peroxidation. , 2016, Trends in cell biology.

[38]  B. Stockwell,et al.  Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. , 2015, Bioorganic & medicinal chemistry letters.

[39]  Tom Mikkelsen,et al.  High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. , 2015, ACS medicinal chemistry letters.

[40]  G. Farshid,et al.  XI-006 induces potent p53-independent apoptosis in Ewing sarcoma , 2015, Scientific Reports.

[41]  J. V. van Meerbeeck,et al.  The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer , 2015, Oncotarget.

[42]  B. Stockwell,et al.  Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective , 2015, Proceedings of the National Academy of Sciences.

[43]  W. Gu,et al.  Ferroptosis as a p53-mediated activity during tumour suppression , 2015, Nature.

[44]  A. Walch,et al.  Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice , 2014, Nature Cell Biology.

[45]  B. Chauffert,et al.  Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. , 2014, Anticancer research.

[46]  R. Fåhraeus,et al.  MDM2’s social network , 2014, Oncogene.

[47]  B. Stockwell,et al.  Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models , 2014, Journal of the American Chemical Society.

[48]  C. M. Eischen,et al.  Mdmx promotes genomic instability independent of p53 and Mdm2 , 2014, Oncogene.

[49]  Yongmei Yin,et al.  MDM2 Promotes Invasion and Metastasis in Invasive Ductal Breast Carcinoma by Inducing Matrix Metalloproteinase-9 , 2013, PloS one.

[50]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.

[51]  W. El-Deiry,et al.  p21WAF1 and tumourigenesis: 20 years after , 2013, Current opinion in oncology.

[52]  J. Momand,et al.  Identification of FDA‐approved Drugs that Computationally Bind to MDM2 , 2012, Chemical biology & drug design.

[53]  H. Anders,et al.  MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice. , 2012, Kidney international.

[54]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[55]  C. M. Eischen,et al.  Protecting the genome from mdm2 and mdmx. , 2012, Genes & cancer.

[56]  G. Lozano,et al.  The Many Faces of MDM2 Binding Partners. , 2012, Genes & cancer.

[57]  C. Prives,et al.  Mdm2 and MdmX as Regulators of Gene Expression. , 2012, Genes & cancer.

[58]  Paras Gupta,et al.  The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases , 2011, Journal of advanced pharmaceutical technology & research.

[59]  B. Stockwell,et al.  Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. , 2011, Cancer discovery.

[60]  H. Kawai,et al.  The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo , 2011, Proceedings of the National Academy of Sciences.

[61]  L. Kaltenbach,et al.  Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay , 2011, Neurobiology of Disease.

[62]  Hongbo Wang,et al.  A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. , 2011, Neoplasia.

[63]  Roderick T. Hori,et al.  Peroxisome proliferator activated receptor α (PPARα) and PPAR gamma coactivator (PGC-1α) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements , 2010, Molecular and Cellular Endocrinology.

[64]  J. Manfredi.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. , 2010, Genes & development.

[65]  Ker-Chau Li,et al.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug , 2009, Nature Cell Biology.

[66]  Ker-Chau Li,et al.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug , 2009, Nature Cell Biology.

[67]  J. V. Vanden Heuvel,et al.  Regulation of peroxisome proliferator-activated receptor-alpha by MDM2. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[68]  Baoying Huang,et al.  Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation , 2008, Cell cycle.

[69]  H. Steinman,et al.  MdmX Promotes Bipolar Mitosis To Suppress Transformation and Tumorigenesis in p53-Deficient Cells and Mice , 2007, Molecular and Cellular Biology.

[70]  S. Kersten.  Review Article Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism , 2022 .

[71]  K. Vousden,et al.  An essential function of the extreme C‐terminus of MDM2 can be provided by MDMX , 2007, The EMBO journal.

[72]  A. Kentsis,et al.  The Mdm2 RING domain C‐terminus is required for supramolecular assembly and ubiquitin ligase activity , 2007, The EMBO journal.

[73]  Mengjia Tang,et al.  Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells* , 2006, Journal of Biological Chemistry.

[74]  G. Stark,et al.  Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. , 2006, Cancer research.

[75]  N. Westwood,et al.  Pilot screening programme for small molecule activators of p53 , 2005, International journal of cancer.

[76]  K. Conklin.  Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity , 2005, Integrative cancer therapies.

[77]  D. V. van Raalte,et al.  Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future , 2004, Pharmaceutical Research.

[78]  A. Jochemsen,et al.  Mdmx and Mdm2: Brothers in Arms? , 2004, Cell cycle.

[79]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[80]  Bohdan Wasylyk,et al.  p53-independent functions of MDM2. , 2003, Molecular cancer research : MCR.

[81]  S. Deb.  Cell cycle regulatory functions of the human oncoprotein MDM2. , 2003, Molecular cancer research : MCR.

[82]  S. Berberich,et al.  MdmX inhibits Smad transactivation , 2002, Oncogene.

[83]  Z. Ronai,et al.  p53-Mdm2--the affair that never ends. , 2002, Carcinogenesis.

[84]  E. Ségal-Bendirdjian,et al.  Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms , 2001, Oncogene.

[85]  B. Staels,et al.  Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators , 2000, Clinical chemistry and laboratory medicine.

[86]  Samir Guglani.  Death , 1890, The Lancet.

[87]  A. D’Alessandro,et al.  Untargeted and Semi-targeted Lipid Analysis of Biological Samples Using Mass Spectrometry-Based Metabolomics. , 2019, Methods in molecular biology.

[88]  R. Mitra,et al.  Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells. , 2017, Cancer research.

[89]  A. Sanz,et al.  Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid-Induced AKI. , 2017, Journal of the American Society of Nephrology : JASN.

[90]  K. Bielskienė,et al.  E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. , 2015, Medicina.

[91]  J. Manfredi,et al.  p53-independent effects of Mdm2. , 2014, Sub-cellular biochemistry.

[92]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[93]  S. Deb.  Function and dysfunction of the human oncoprotein MDM2. , 2002, Frontiers in bioscience : a journal and virtual library.

[94]  J. Auwerx,et al.  Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. , 1996, Journal of atherosclerosis and thrombosis.